Home / News / India News / Article /
DGCI approves for phase 3 trial of Bharat Biotech intranasal vaccine as booster
Updated On: 05 January, 2022 01:07 PM IST | New Delhi | ANI
Earlier, Bharat Biotech’s covid-19 vaccine Covaxin has received approval for emergency use in Children 12 - 18 years of age
Listen to this article :
_d.jpg "DGCI approves for phase 3 trial of Bharat Biotech intranasal vaccine as booster")
This image has been used for representation purpose
The Subject Experts Committee (SEC) of the Drug Controller General of India (DGCI) on Wednesday granted "in principle" approval to Bharat Biotech to conduct "Phase III superiority study and Phase III booster dose study" trials for its intranasal Covid vaccine.
The approval was sought by the vaccine manufacturer last week.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT